Clinical Research, Pharma & Healthcare FinancingBristol Myers Squibb Gets CHMP Opinion for Breyanzi in LymphomaBusiness WireFebruary 3, 2025February 12, 2025 by Business WireFebruary 3, 2025February 12, 2025032 Recommendation based on the Phase 2 TRANSCEND FL study in which 97.1% of patients responded to Breyanzi, with 94.2% of patients achieving complete response Across clinical...
